Literature DB >> 29572669

Good glycaemic control is associated with a better prognosis in breast cancer patients with type 2 diabetes mellitus.

Yen-Lin Chang1, Wayne Huey-Herng Sheu2,3,4,5, Shih-Yi Lin6,5, Wen-Shyong Liou7,8.   

Abstract

Although diabetes mellitus (DM) is one of the risk factors associated with increased breast cancer (BC) mortality, the effects of glycaemic control on the prognosis of BC have not been thoroughly evaluated. This retrospective study aimed to evaluate the relationship between glycaemic control and BC prognosis and to determine an optimal target of glycaemic control for BC patients with diabetes. We included 2812 stage 0-3 BC women, of whom 145 were diabetic and were 2667 non-diabetic. In those with diabetes, a mean haemoglobin A1C (HbA1C) < 7% (n = 77) was defined as well-controlled diabetes, while a mean HbA1C > 9% (n = 16) was defined as poorly controlled diabetes. All of the BC populations were followed from the date on which BC was diagnosed until 31 December 2015. Cox regression analysis was performed to estimate the adjusted hazards for all-cause mortality and BC-specific mortality. After controlling for the baseline and BC-related confounders, the adjusted hazard ratio (HR) for all-cause mortality and the HR for BC-specific mortality were 3.65 (95% confidence interval [95% CI] 1.13-11.82) and 8.37 (95% CI 1.90-36.91), respectively, for poorly controlled diabetic women and non-DM women. However, for the diabetic women with good glycaemic control, the HRs of all-cause mortality and BC-specific mortality were not significantly different (HR 0.91, 95% CI 0.42-1.01; HR 0.77, 95% CI 0.18-3.32, respectively) from those for both mortalities in non-DM patients. For moderate controlled diabetic women, the HRs for all-cause mortality and BC-specific mortality were 1.95 (95% CI 0.89-4.27) and 3.55 (95% CI 1.369-9.30), respectively. This pilot and retrospective cohort study reveals a relationship between glycaemic control and BC prognosis in diabetic women. In addition, well-controlled HbA1C, with maintained mean HbA1C values under 7%, may be associated with a better progression outcome of BC.

Entities:  

Keywords:  Breast cancer; Diabetes mellitus; Haemoglobin A1C; Mortality

Mesh:

Substances:

Year:  2018        PMID: 29572669     DOI: 10.1007/s10238-018-0497-2

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  27 in total

1.  Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population.

Authors:  C L Rohlfing; R R Little; H M Wiedmeyer; J D England; R Madsen; M I Harris; K M Flegal; M S Eberhardt; D E Goldstein
Journal:  Diabetes Care       Date:  2000-02       Impact factor: 19.112

Review 2.  6. Glycemic Targets.

Authors: 
Journal:  Diabetes Care       Date:  2017-01       Impact factor: 19.112

3.  Epidemiology of diabetes and diabetes complications in the elderly: an emerging public health burden.

Authors:  Mark Corriere; Nira Rooparinesingh; Rita Rastogi Kalyani
Journal:  Curr Diab Rep       Date:  2013-12       Impact factor: 4.810

4.  Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome.

Authors:  Ben Boursi; Bruce J Giantonio; James D Lewis; Kevin Haynes; Ronac Mamtani; Yu-Xiao Yang
Journal:  Eur J Cancer       Date:  2016-03-25       Impact factor: 9.162

5.  Medical comorbidities predict mortality in women with a history of early stage breast cancer.

Authors:  Ruth E Patterson; Shirley W Flatt; Nazmus Saquib; Cheryl L Rock; Bette J Caan; Barbara A Parker; Gail A Laughlin; Kirsten Erickson; Cynthia A Thomson; Wayne A Bardwell; Richard A Hajek; John P Pierce
Journal:  Breast Cancer Res Treat       Date:  2010-01-14       Impact factor: 4.872

6.  Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes.

Authors:  Hee Jeong Kim; Hyunwook Kwon; Jong Won Lee; Hwa Jung Kim; Sae Byul Lee; Hee Sung Park; Guiyun Sohn; Yura Lee; Beom Seok Koh; Jong Han Yu; Byung Ho Son; Sei Hyun Ahn
Journal:  Breast Cancer Res       Date:  2015-05-03       Impact factor: 6.466

Review 7.  Hyperglycemia, a neglected factor during cancer progression.

Authors:  Wanxing Duan; Xin Shen; Jianjun Lei; Qinhong Xu; Yongtian Yu; Rong Li; Erxi Wu; Qingyong Ma
Journal:  Biomed Res Int       Date:  2014-04-17       Impact factor: 3.411

Review 8.  Hyperglycemia as a risk factor for cancer progression.

Authors:  Tae Young Ryu; Jiyoung Park; Philipp E Scherer
Journal:  Diabetes Metab J       Date:  2014-10       Impact factor: 5.376

9.  Relationship between level of HbA1C and breast cancer.

Authors:  Fariba Jousheghany; Joshua Phelps; Tina Crook; Reza Hakkak
Journal:  BBA Clin       Date:  2016-04-23

Review 10.  Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis.

Authors:  Xiao-Bo Zhao; Guo-Sheng Ren
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.817

View more
  5 in total

1.  Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Authors:  Stefania Maraka; Morris D Groves; Aaron G Mammoser; Isaac Melguizo-Gavilanes; Charles A Conrad; Ivo W Tremont-Lukats; Monica E Loghin; Barbara J O'Brien; Vinay K Puduvalli; Erik P Sulman; Kenneth R Hess; Kenneth D Aldape; Mark R Gilbert; John F de Groot; W K Alfred Yung; Marta Penas-Prado
Journal:  Cancer       Date:  2018-10-25       Impact factor: 6.860

2.  Patterns of chronic disease management and health outcomes in a population-based cohort of Black women with breast cancer.

Authors:  Michelle Doose; Jennifer Tsui; Michael B Steinberg; Cathleen Y Xing; Yong Lin; Joel C Cantor; Chi-Chen Hong; Kitaw Demissie; Elisa V Bandera
Journal:  Cancer Causes Control       Date:  2021-01-06       Impact factor: 2.506

Review 3.  Epidemiological characteristics of and risk factors for breast cancer in the world.

Authors:  Zohre Momenimovahed; Hamid Salehiniya
Journal:  Breast Cancer (Dove Med Press)       Date:  2019-04-10

4.  The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus.

Authors:  Jie Qian; Weimin Wang; Lin Wang; Jun Lu; Lele Zhang; Bo Zhang; Shuyuan Wang; Wei Nie; Yanwei Zhang; Yuqing Lou; Baohui Han
Journal:  Front Oncol       Date:  2021-11-16       Impact factor: 6.244

5.  Influence of Hyperglycemia on the Prognosis of Patients with Diffuse Large B-Cell Lymphoma.

Authors:  Weiling Zhou; Weijing Li; Cuiying He; Ruijuan Ma; Qian Gao; Yuan Wang; Lei Feng; Lihong Liu
Journal:  Diabetes Metab Syndr Obes       Date:  2022-07-13       Impact factor: 3.249

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.